Assessing the Efficacy of Combined Tenofovir and Atorvastatin Therapy in Chronic Hepatitis B
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 5th, 2025
|
Chronic hepatitis B infection can be managed through interferon and antiviral therapies; however, no current treatment effectively eradicates the virus. During its life cycle, the hepatitis B virus incorporates a portion of the host cell membrane as it exits the cell. Since cholesterol plays a key role in determining membrane flexibility, a study was conducted to investigate whether adding a cholesterol-lowering statin to standard antiviral therapy could improve hepatitis B control.
The prospective clinical study took place in Iran and involved 43 individuals diagnosed with active hepatitis B infection. Their mean baseline HBV DNA level was roughly 1.6 billion copies per mL. These participants also had elevated liver enzyme levels, with average initial AST and ALT measurements of approximately 63 IU/mL and 70 IU/mL, respectively.
The patients received a standard antiviral regimen of tenofovir disoproxil fumarate (300 mg, twice daily for 12 months). This medication inhibits the hepatitis B virus’s reverse transcriptase enzyme, preventing the formation of viral DNA that can integrate into the host genome and establish chronic infection. Additionally, participants were randomly assigned to receive either a placebo or 40 mg of atorvastatin per day. Atorvastatin is an antihypercholesterolemic agent that lowers cholesterol production by inhibiting HMG-CoA reductase.
After one month of treatment, patients receiving both tenofovir and atorvastatin showed a markedly lower level of HBV DNA compared to those on tenofovir alone. By the third month, the virus was undetectable in about half of the combination-therapy group, whereas only 30% of the monotherapy group achieved this outcome. Over the 12-month treatment period, however, there was no significant difference in ALT and AST levels between the two groups. The researchers further hypothesized that atorvastatin may help inhibit viral entry by binding to and blocking the sodium taurocholate cotransporting polypeptide receptor, which the hepatitis B virus uses to infect host cells. They emphasized the need for further studies to evaluate both the long-term effectiveness and safety of the combined regimen, as well as to investigate the durability of viral suppression once treatment is discontinued.
The prospective clinical study took place in Iran and involved 43 individuals diagnosed with active hepatitis B infection. Their mean baseline HBV DNA level was roughly 1.6 billion copies per mL. These participants also had elevated liver enzyme levels, with average initial AST and ALT measurements of approximately 63 IU/mL and 70 IU/mL, respectively.
The patients received a standard antiviral regimen of tenofovir disoproxil fumarate (300 mg, twice daily for 12 months). This medication inhibits the hepatitis B virus’s reverse transcriptase enzyme, preventing the formation of viral DNA that can integrate into the host genome and establish chronic infection. Additionally, participants were randomly assigned to receive either a placebo or 40 mg of atorvastatin per day. Atorvastatin is an antihypercholesterolemic agent that lowers cholesterol production by inhibiting HMG-CoA reductase.
After one month of treatment, patients receiving both tenofovir and atorvastatin showed a markedly lower level of HBV DNA compared to those on tenofovir alone. By the third month, the virus was undetectable in about half of the combination-therapy group, whereas only 30% of the monotherapy group achieved this outcome. Over the 12-month treatment period, however, there was no significant difference in ALT and AST levels between the two groups. The researchers further hypothesized that atorvastatin may help inhibit viral entry by binding to and blocking the sodium taurocholate cotransporting polypeptide receptor, which the hepatitis B virus uses to infect host cells. They emphasized the need for further studies to evaluate both the long-term effectiveness and safety of the combined regimen, as well as to investigate the durability of viral suppression once treatment is discontinued.